Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics

The distinguished translational oncology researchers on Unum’s Scientific Advisory Board (SAB) provide counsel to support continued development of our ACTR platform, and provide us with key insights as we develop our broader research agenda. Comprised of pioneers in immuno-oncology, our SAB includes:

 

 

Dario Campana, MD, PhD
Chair

Bio

 

Malcom Brenner, MD, PhD

Bio

 

John Gribben, MD, DSc, FRCP, FRCPath, FMedSci

Bio

 

Crystal Mackall, MD

Bio

Dario Campana, MD, PhD

Scientific Founder
 

Dario is the scientific founder of the company, and a leader in the field of cancer cell therapies. At the National University of Singapore (NUS), Dario developed the ACTR technology that forms the basis for Unum. At St. Jude Children’s Research Hospital, he created the CD19 chimeric antigen receptor (CAR) that was subsequently shown to be highly effective in treating patients with Acute Lymphoblastic Leukemia (ALL), an aggressive form of the disease. He has extensive experience managing clinical cell therapy trials in oncology. He received his MD from the University of Torino and his PhD from the University of Milan.